Table 3.
Differences between care partners and persons with Parkinson's disease before and after seven weeks of participation in the National Parkinson School (intervention group) and after seven weeks of ordinal care (control group)a.
| Intervention group (n = 30) | Control group (n = 25) | P-valueb | ||
|---|---|---|---|---|
| Health valuation (EQ5D)d | Baseline | 0.93 (0.88–0.97) | 0.93 (0.88–0.97) | 0.508 |
| Follow-up | 0.97 (0.88–0.97) | 0.93 (0.88–0.97) | 0.251 | |
| P-valuec | 0.837 | 0.944 | ||
|
| ||||
| Life satisfaction (LiSat-11)e | ||||
| Life as a whole | Baseline | 5 (4–5) | 5 (4–6) | 0.302 |
| Follow-up | 5 (4–5) | 5 (4–6) | 0.802 | |
| P-valuec | 0.414 | 0.035 | ||
|
| ||||
| Vocation | Baseline | 5 (4–5) | 5 (4–5.75) | 0.388 |
| Follow-up | 5 (4.25–5) | 5 (4–5) | 0.261 | |
| P-valuec | 0.655 | 0.109 | ||
|
| ||||
| Economy | Baseline | 5 (5–5) | 5 (5–5.25) | 0.515 |
| Follow-up | 5 (4–5.25) | 5 (4–5) | 0.945 | |
| P-valuec | 0.317 | 0.132 | ||
|
| ||||
| Leisure | Baseline | 5 (4–5) | 5 (4.75–5) | 0.072 |
| Follow-up | 5 (4–5) | 5 (4–5) | 0.964 | |
| P-valuec | 0.248 | 0.206 | ||
|
| ||||
| Contacts | Baseline | 5 (5–5) | 5 (4–5.25) | 0.666 |
| Follow-up | 5 (4–5) | 5 (4–6) | 0.671 | |
| P-valuec | 0.366 | 0.564 | ||
|
| ||||
| Sexual life | Baseline | 4 (2–5) | 4 (3.5–5) | 0.509 |
| Follow-up | 4 (3–5) | 4 (2.25–5) | 0.776 | |
| P-valuec | 0.491 | 0.417 | ||
|
| ||||
| ADL | Baseline | 6 (5–6) | 6 (5–6) | 0.586 |
| Follow-up | 6 (5–6) | 6 (5.25–6) | 0.486 | |
| P-valuec | 0.891 | 0.317 | ||
|
| ||||
| Family life | Baseline | 5 (4–6) | 5.5 (5–6) | 0.227 |
| Follow-up | 6 (5–6) | 6 (5–6) | 0.801 | |
| P-valuec | 0.290 | 0.655 | ||
|
| ||||
| Partner relationship | Baseline | 6 (5–6) | 6 (5–6) | 0.773 |
| Follow-up | 6 (5–6) | 6 (5–6) | 0.792 | |
| P-valuec | 0.763 | 0.705 | ||
|
| ||||
| Somatic health | Baseline | 5 (4–5) | 5 (4–5) | 0.805 |
| Follow-up | 5 (5–5) | 5 (4–5) | 0.659 | |
| P-valuec | 0.739 | 0.655 | ||
|
| ||||
| Psychological health | Baseline | 5 (5–6) | 5 (4.75–6) | 0.371 |
| Follow-up | 5 (5–6) | 5 (4.5–6) | 0.851 | |
| P-valuec | 0.279 | 0.180 | ||
|
| ||||
| Fatigue (PFS-16)f | Baseline | 9 (0–17.75) | 5 (1–19) | 0.661 |
| Follow-up | 6 (0–20) | 11.5 (1.25–25) | 0.296 | |
| P-valuec | 0.678 | 0.138 | ||
|
| ||||
| Caregiver burden (ZBI-22)g | Baseline | 7 (3–13) | 6 (0.75–12.5) | 0.495 |
| Follow-up | 8 (3.25–12.75) | 5 (2–13.25) | 0.659 | |
| P-valuec | 0.090 | 0.548 | ||
aData are median (q1-q3). bMann–Whitney U test for comparisons between intervention and control groups. cWilcoxon's signed rank test for comparisons between baseline and follow-up within intervention and control groups. dPossible scores, 0-1 (1 = better valued health state). ePossible scores, 1–6 (6 = higher life satisfaction). fPossible scores, 0–64 (64 = more fatigue). gPossible scores, 0–48 (48 = more burden). EQ5D: the 5-dimensional EuroQol questionnaire; LiSat-11: the 11-item Life Satisfaction Checklist; PFS-16: the 16-item Parkinson Fatigue Scale; zbi-22: the 22-item Zarit Burden Interview.